Dennis Marshall

Dennis C. Marshall, RN, MS, PhD, began work at Chilton Memorial Hospital, Pompton Plains, NJ, as an Emergency Medical Technician in 1967-1970 and then moved to Greystone Psychiatric Hospital, NJ, as a Charge Attendant on Maximum Security and Admission Units, 1970-1976. During that time, he earned his A.A.S. degree from County College of Morris and his licensure as a Registered Professional Nurse from the State University of New York. From 1976-1981, he worked as a Psychiatric Nurse on Assaultive Behavior, Intermediate Care and Admission Units at Lyons, Veterans Administration Medical Center, NJ. During that time, he earned B.S. degrees in Biology, Chemistry and Psychology from Fairleigh Dickinson University and William Paterson College, and his M.S. degree, suma cum laude, in Human Physiology from the Fairleigh Dickinson School of Dental Sciences. In 1981, he began studies at the Medical College of Georgia and earned his Ph.D. in Pharmacology, with distinction, three years later.

In 1984, Dr. Marshall joined the Drug Research and Discovery efforts of Berlex Laboratories Inc, in the General and Vascular pharmacology laboratories. He then moved to Pfizer Inc, NY, in 1986, where he held positions of increasing responsibility in Drug Development with Scientific Affairs and Worldwide Drug Safety. In 1999, Dr. Marshall moved to Ferring Pharmaceuticals Inc, as Executive Director, Medical Affairs. From 1984 to the present, he has held adjunct faculty positions in Pharmacology, Physiology and Allied Health Sciences at Fairleigh Dickinson University and the University of Medicine and Dentistry of New Jersey.

Dr Marshall’s clinical, academic and industry experience encompasses the research of conditions and development of drugs in the areas of neuropharmacological, cardiovascular, urological, renal and endocrine medicine. He has published more than 70 research and clinical papers and is an active member of numerous medical and scientific organizations.

Dennis C. Marshall
Executive Director, Medical Affairs and Clinical Operations
Ferring Pharmaceuticals Inc,
4 Gatehall Drive, Parsippany, NJ 07054
Tel: 973-796-1685 Email: dennis.marshall@ferring.com
CAREER SUMMARY
Senior pharmaceutical executive with in-depth experience in the planning, implementation and management of U.S. and international discovery, R&D, and post-marketing clinical development programs. Broad experience at the medical/regulatory/marketing/sales interface. Extensive experience in clinical, academic and industry medical/biomedical research, 70 peer-reviewed publications, 8 INDs, 9 NDAs, 2 IRDs, writing, public speaking, contract/ agreement negotiations and technology assessment.
PROFESSIONAL EXPERIENCE
Ferring Pharmaceuticals, Inc, Suffern, NY
Executive Director, Medical Affairs and Clinical Operations 1999 to Present
􀂾 Created and manage the Department of Medical Affairs: established Fertility, Orthopaedic/Urology and Drug Safety Groups with product/clinical development/marketing support and corporate functions
􀂾 Design/implement/manage multimillion dollar Phase I/II/III/IIIb/IV clinical studies: FDA contacts
􀂾 Created U.S. drug safety databases and linked them to international pharmacovigilance operations
􀂾 Linked Medical Affairs with leading academic/clinical centers, professional associations, top tier journals and internationally respected thought leaders; co-authorship on numerous publications
􀂾 Design/Established medical/marketing system to document and track health professional/consumer queries
􀂾 Established the infrastructure, processes and procedures to identify, acquire, consolidate, and appropriately disseminate R&D, clinical and non-clinical data in support of Marketing and Sales operations
􀂾 Guide marketing strategy and manage promotional materials review for device and drugs
􀂾 Lead a joint venture injection-device global development program (510k)
􀂾 Strategic assessments of new drug pipeline, drug patents and in-licensing opportunities
Pfizer Inc, New York, NY 1986 to 1999
Senior Associate Director, Worldwide Safety 1997 to 1999
Overall responsibility for the preparation, data interpretation and distribution of Pharmacovigilance and Periodic Safety Update Reports for all Pfizer products
􀂾 Managed the compilation/evaluation/review/reporting and worldwide distribution of the safety experience of all products in the context of market exposure data and government agency regulations
Senior Associate Director, Scientific Affairs, Pfizer Pharmaceuticals Group 1992-1997
Global management and budgeting of Scientific Affairs associated with the development and commercialization of several billion dollar products in several therapeutic categories including sertraline (Zoloft®), azithromycin (Zithromax®), nifedipine (Procardia®) doxazosin (Cardura®) for hypertension and benign prostatic hyperplasia (BPH), and amlodipine (Norvasc®); commercialization of atorvastatin (Lipitor®) and sildenafil (Viagra®)
􀂾 Managed the study design, acquisition, processing, analysis, evaluation and reporting of clinical efficacy and safety data for presentations, publications, International Registration Dossiers and New Drug Applications; frequent data discussion with FDA
􀂾 Responsible for scientific content, selection of opinion-leader participants and budgeting of the mechanism of action programs
􀂾 Responsible for the assessment of technology, clinical and non-clinical data related to potential licensing candidates
􀂾 Developed a worldwide electronic product bibliography and speakers directory, including copyright negotiations and privacy rights, which served a model for other product areas
􀂾 Chairperson/Co-Chairperson/member of numerous task forces including the reorganization of International Pharmaceuticals Group; improving the drug candidate development process; standards for clinical reports and safety data processing
DCM.dec07
Dennis C. Marshall, RN, PhD page 2 of 8
Associate Director, Scientific Affairs, Pfizer International, Inc 1988-1992
Provided scientific guidance and direction for Phase II, III and IV clinical studies and provided strategic direction to marketing plans in therapeutic areas of cardiovascular, urology, central nervous system and respiratory.
􀂾 Designed drug development strategies with project teams; trained Clinical Research Associates
􀂾 Wrote more than 100 clinical study reports, position papers and regulatory submissions (IRDs/NDAs)
Assistant Director, Scientific Affairs, Pfizer International, Inc 1986-1988
Responsible for establishing the clinical data analysis process; management of CRAs in support of medical and marketing needs in the medical and product development processes.
Fairleigh Dickinson University, Madison, NJ 1990-Present
Adjunct Professor Pharmacology and Human Physiology
Design and teach graduate courses on physiology and the drug development process.
Berlex Laboratories, Cedar Knolls, NJ 1984-1986
Research Pharmacologist, Drug Discovery and Development
Responsible for the development and overall management and development of the general pharmacology laboratories: in vitro and in vivo model development for antiarrhythmic, antihypertensive, positive inotropic and antianxiety agents. Chairperson, Research and Development Seminar Committee.
Medical College of Georgia, Augusta, GA 1982-1984
Assistant Instructor: Graduate Student
Prepared/presented lectures/assist in lab demonstrations to undergraduate and medical students on corticosteroids, gastrointestinal drugs, oral contraceptives, cardiovascular medications and neuropharmacologically active agents.
Fairleigh Dickinson University, Teaneck/Hackensack, NJ 1979-1981
Assistant Instructor, Advanced Human Physiology
Veterans Administration Medical Center, Lyons, NJ 1977-1981
Head Nurse, Psychiatric Admission and Assaultive Behavior Units
Responsible for all aspects of 24-hr staffing of 30-36 RNs/LPNs and assistants and delivery of patient care for Maximum Security/Assaultive Behavior and Psychiatric Admissions Units.
􀂾 Managed the safety, interventional therapy, medication, documentation, clinical research studies, GCPs related to 50-70 psychiatric inpatients; crisis intervention and in-service workshops
Greystone State Psychiatric Hospital, Greystone Park, NJ 1970-1976
Psychiatric Charge Attendant, Maximum Security and Admission Units
Established 24-hr routines and interventions for 70-120 severely disturbed incarcerated psychiatric patients.
􀂾 Created, trained and managed a Crisis Intervention Team; conducted Reality Training, Reorientation Therapy and Behavior Modification Groups
Chilton Memorial Hospital, Pompton Plains, NJ 1967-1970
Technician, Emergency Room and Clinical Laboratory Services
EDUCATION
Ph.D., "With Distinction", Pharmacology, Medical College of Georgia 1984
M.S., Summa Cum Laude, Human Physiology, Fairleigh Dickinson College of Dental Medicine 1981
B.S., Magna Cum Laude, Chemistry and Biology, Fairleigh Dickinson University 1977
R.N., Registered Professional Nurse, State University of New York, License #288107 1976
A.A.S., Cum Laude, County College of Morris 1976
DCM.dec07
D.C.Marshall Page 3 of 8
AFFILIATIONS, ACTIVITIES and PUBLICATIONS
PROFESSIONAL AFFILIATIONS
American Association for the Advancement of Science (AAAS); American Heart Association (AHA); American Physiological Society (APS); American Society of Hypertension (ASH); American Society for Pharmacology and Experimental Therapeutics (ASPET); American Society for Reproductive Medicine (ASRM); British Brain Research Association (BBRA); European Brain and Behavior Society (EBBS); New York Academy of Science (NYAS); Sigma Xi, Scientific Research Society of North America; Society for Experimental Biology and Medicine(SEBM); Society for Neuroscience.
COMMITTEES/EDITORIAL REVIEW
• Member, Council of Divisional Chairpersons ASPET 2007-present
• Chairperson, Division of Systems and Integrative Pharmacology, ASPET 2007-present
• Reviewer, Fertility and Sterility 2005-present
• Executive Committee, Division for Systems and Integrative Pharmacology, ASPET 2001-present
• Secretary/Treasurer, Division for Systems and Integrative Pharmacology, ASPET 2001-2004
• Executive Management Committee, Pfizer Worldwide Safety Group 1997-1999
• Science Staff Consultant, NY Academy of Sciences/National Executive Service Corps 1991-1997
• Member, End Game Task Force, Pfizer, Redesign of Discovery/Development Process 1994-1995
• Member, Safety Standards Task Force, Pfizer 1992-1993
• Member, Document Management Task Force, Pfizer 1991-1992
• Member, Team Concept Evaluation Committee 1989-1990
• Field Editor, Drug Development Research 1986-1988
• Chairman, Research and Development Seminar Committee, Berlex 1985-1986
• Vice-President, Society for Neuroscience, CSRA Chapter 1982-1984
• Member, Nurse Professional Standards Board, Veterans Administration 1979-1981
• Member, Advisory Committee on Ethics, Veterans Administration 1979-1981
• Secretary, Nursing Research Committee, Veterans Administration 1978-1981
Summary: HONORS/AWARDS/INTERVIEWS
Rheumatology News: “Euflexxa as Effective as Synvisc in Knee OA, With Fewer Effusions”. Published interview with Doug Brunk; Vol 5 (5), p 4, May 2006.
Oprah “O” magazine: “Is this any way to have a baby?”. Published Interview with Dr Barbara Seaman on medical developments associated with in vitro fertilization; p 188, Feb 2003.
Appointed Focus Group Member, New York Academy of Science, New York, NY (SP3ARK: Science Process, Practice, and Presentation: Applying Resources and Knowledge); convened to consolidate the efforts of several educational organizations into a unified, high intensity program for the New York City school system; September 1996.
Invited Speaker, New York Academy of Sciences, New York, NY: “Our Classroom Successes in
the National Executive Service Corps”, April 1995.
Invited Speaker, New York Academy of Sciences, New York, NY: "Educational Initiatives Which Bring Science to Life", November 1994.
Distinguished Alumnus Award, Medical College of Georgia, Augusta, Georgia; Distinguished Alumnus Lecture, "Changing Times in the Partnership Between Academia and the Pharmaceutical Industry: We're Part of the Cure", April 1994.
DCM.dec07
D.C. Marshall Page 4 of 8
Invited Speaker, Rockefeller University, New York, NY: "The Cooperation Between Industry and the Public School System in New York City", March 1994.
Co-Chairman, Neuroscience symposium, "Insights Into Brain and Spinal Components of the Opiate Withdrawal Syndrome"; 21st Annual Meeting, Society for Neuroscience, November 1991.
Television Guest, Joan Lunden show "Everyday" WOR-TV, Secaucus, NJ. Discussions on
physiological mechanisms associated with high-risk pregnancy, October 1989.
Invited Lecturer, Lincoln Hospital, Bronx, NY, January 1986-1988
Research Associate in Pharmacology, National Institutes of Health, Bethesda, MD, January 1985 to January 1987, declined invitation.
Research Travel Award, International Kinin Congress, Savannah, GA, 1984.
Research Travel Award, American Society for Pharmacology and Experimental Therapeutics, Indianapolis, IN, August 1984.
Research Scholarship Award, Faculty Wives Scholarship, Medical College of Georgia, Augusta, GA, June 1983 to June 1984.
Who's Who Among Students in American Universities and Colleges, October 1984.
Honorable Mention, Research Day Competition, Medical College of Georgia, Augusta, GA,
December 1983.
Travel Award for Research, Society for Experimental Biology and Medicine, S.E. Section, Richmond, VA, November 1983.
Third Place Research Award, Society for Experimental Biology and Medicine, S.E. Section, Richmond, VA, November 1983.
First Place Research Award, Southeastern Pharmacology Society, Research Competition,
Birmingham, AL, October 1983.
Television Interviews, WAGT (ABC affiliate) and WRDW (CBS affiliate) television networks, Augusta, GA. Interviews on blood pressure research and graduate education, September 1983.
Honorable Mention, Southeastern Pharmacology Society, Research Competition, Oxford, MS, October 1982.
Director's Performance Citation, Carl M. Mikail Achievement Award, Lyons V.A. Medical Center, Lyons, NJ, September 1981.
Certificate of Appreciation, Cornelia Thompson Letter of Commendation, Lyons V.A. Medical
Center, Lyons, NJ, November 1978.
New Jersey State Scholarship for Nursing, June 1974 to June 1976.
Community Service Award, Pequannock Township and Chilton Memorial Hospital, Pompton Plains, NJ, September 1970.
PUBLICATIONS
Kirchner M and Marshall DC. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 14(2):154-162, 2006
Scobey MJ, Raike E, Marshall DC. Mixed Protocols: Multiple Ratios of FSH and LH bioactivity using highly purified, human-derived FSH (BRAVELLE®) and highly purified hMG (MENOPUR®) are unaltered by mixing together in the same syringe. Repro Bio Endo www.rbej.com/content/3/1/61, 2005
Hatoum HT, Keye WR, Marrs RP, Walton SM, Marshall DC. A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data. Fertil Steril 83:804-807, 2005
DCM.dec07
D.C. Marshall Page 5 of 8
Keye WR, Marrs RP, Check JH, Schnell V, Surrey M, Marshall DC. Evaluation of mixed protocols with Bravelle® (human-derived FSH) and Repronex® (hMG) to assess clinical efficacy (EMBRACE) in women undergoing in vitro fertilization. Fertil Steril 82:348-357, 2004
Dickey RP, Nichols JE, Steinkampf MP, Gocial B, Thornton M, Webster BW, Bellow SM, Crain J, Marshall DC. Highly purified human-derived follicle-stimulating hormone (Bravelle®) has equivalent efficacy to follitropin-beta (Follistim®) in infertile women undergoing in vitro fertilization. Reprod Biol Endocrin 1:63, 2003.
Dickey RP, Thornton M, Nichols J, Marshall DC, Fein SH, Nardi RV for the Bravelle IVF study group. Comparison of the efficacy and safety of a highly purified human follicle-stimulating hormone (Bravelle™) and recombinant follitropin-β for in vitro fertilization: a prospective, randomized study. Fertil Steril 77:1202-1208, 2002.
Feigenbaum SL, Miller P, Kaufmann R, Elkind-Hirsch K, Fein SH, Marshall DC. A new highly purified human-derived FSH, Bravelle™, is as effective and well tolerated as recombinant follitropin beta in ovulation induction in infertile women with ovulatory dysfunction. Today’s Ther Trends 19:297-313, 2001
Nichols J, Knockenhauer E, Fein SH, Nardi RV, Marshall DC and the Repronex SC Ovulation Induction study group. Subcutaneously administered Repronex in oligoovulatory female patients undergoing ovulation induction is as effective and well tolerated as intramuscular human menopausal gonadotropin treatment. Fertil Steril 76:58-66, 2001.
Marshall DC, Raike E, DeSilva M, Nardi RV. Mixed-protocol, same-syringe combination of gonadotropins: compatibility of new, highly purified, human-derived FSH (Bravelle™) and hMG (Repronex®). Today’s Ther Trends 19:213-224, 2001.
Keye, W.R., Marshall, D.C.: Route of Administration and Clinical Efficacy of Gonadotropins. In: Marco Filicori, ed., Endocrine Basis of Reproductive Function. Litosei-Rastignano, Bologna, Italy, 375-382; 2000.
Silva, H., Fonseca, R., Marshall, D.C.: A Non-Comparative Study of the Efficacy and Safety of Doxazosin in the Treatment of Mild and Moderate Essential Hypertension in General Medical Practice. American Heart Journal 121(1): 329-335, 1991.
Lampe, J.W., Hanna, R.G., Piscitelli, T.A., Chou, Y.L., Erhardt, P.W., Lumma, W.C. Jr., Greenberg, S.S., Ingebretsen, W.R., Marshall, D.C., Wiggins, J.: Histamine Analogues as Potential Cardiovascular Selective H2 Agonists. J. Med. Chem. 33 (6): 1688-97, 1990.
Barlage, U., Ansmann, E. and Marshall, D.C.: Postsynaptischer Alpha I Rezeptorenblocker zur Optimierung der Hochdrucktherapie: Blutdruck und Lipidrisiko durch Effektive Kombinationstherapie Senken. Therapiewoche 39: 2230-2234, 1989.
Aronstam, R.S., Marshall, D.C. and Buccafusco, J.J.: Cholinergic False Transmitters: Physiological and Biochemical Actions in Central and Peripheral Systems. Neuropharmacology 27 (3): 217-225, 1988.
Marshall, D.C. and Buccafusco, J.J.: Spinal Cholinergic Neurons and the Expression of Morphine Withdrawal Symptoms in the Rat. J. Neuroscience 7 (3): 621-628, 1987.
Marshall, D.C. and Buccafusco, J.J.: Spontaneous Morphine Withdrawal from the Rat Spinal Cord. Experientia 41: 1151-1152, 1985.
DCM.dec07
D.C. Marshall Page 6 of 8
Buccafusco, J.J. and Marshall, D.C.: Dorsal Root Lesions Block the Expression of Morphine Withdrawal Elicited from the Rat Spinal Cord. Neurosci. Letters 59: 319-324, 1985.
Marshall, D.C. and Buccafusco, J.J.: Supraspinal and Spinal Mediation of Naloxone Induced Morphine Withdrawal in Rats. Brain Res. 329: 131-142, 1985.
Marshall, D.C. and Buccafusco, J.J.: A Comparison of the Cardiovascular and Behavioral
Changes Following Naloxone as Measures of the Degree of Physical Dependence on Morphine in Rats. Drug Dev. Res. 5 (3): 271-280, 1985.
Buccafusco, J.J., Marshall, D.C. and Turner, R.: A Comparison of the Inhibitory Effects of Clonidine and Guanfacine on the Behavioral and Autonomic Components of Morphine Withdrawal in Rats. Life Sci. 35 (13): 1401-1408, 1984.
Carrier, G.O., Marshall, D.C. and Aronstam, R.S.: Calcium Fluxes in Intestinal Smooth Muscle: Influence of Alkylation. Eur. J. Pharmacol. 89: 173-175, 1983.
Morris County Community Health Services Digest: Guide to Health Care Facilities in New Jersey. Eds. Marshall, D.C. and Hunter, J.. County College of Morris Press, 1976.
Abstracts
Hatoum HT, Keye WR, Marrs RP, Surrey M, Marshall DC. A Markov model of the cost effectiveness of a new highly-purified, human-derived FSH versus follitropin-β using comparative clinical trial data. Fertil Steril 80:S140, 2003
Rodriguez AF, Lifchez AS, Witt BR, Scholl GM, Karande VC, Marshall DC. Evaluation of mixed protocols with Bravelle (hFSH) and Repronex (hMG) to assess clinical efficacy (EMBRACE): a comparison of patients 18-33 years and 34-40 years undergoing in vitro fertilization. Fertil Steril 80:S69, 2003
Dickey RP, Nichols JE, Steinkampf MP, Gocial B, Crain JL, Webster BW, Scobey MJ, Marshall DC. Bravelle™ (highly-purified hFSH) vs. Follistim® (rFSH) in IVF: pooled analysis from two prospective, randomized clinical trials. Fertil Steril 79: S17, 2003
Marrs RP, Check JH, Schnell VL, Jacobs MH, Yemini M, Oskowitz SP, Batzofin JH, Houserman VL, Marshall DC for the EMBRACE study group. Evaluation of mixed protocols with Bravelle (hFSH) and Repronex (hMG) to assess clinical efficacy (EMBRACE I) in patients (18-33 years) undergoing in vitro fertilization. Fertil Steril 79:S14, 2003
Keye WR, Surrey MW, Van Voorhis BJ, Kenigsberg DJ, Check JH, McShane PM, Eisermann J, Scheiber MD, Westphal LM, Marshall DC for the EMBRACE study group. Evaluation of mixed protocols with Bravelle (hFSH) and Repronex (hMG) to assess clinical efficacy (EMBRACE II) in patients (34-40 years) undergoing in vitro fertilization. Fertil Steril 79:S6, 2003
Marshall DC, Raike EA, DeSilva M, Nardi RV. The bioactivities of FSH and LH are unaltered by mixing highly purified human-derived FSH (Bravelle™) and HMG (HP-Repronex®) together in the same diluent and in the same syringe. Fertil Steril 77:S19, 2002
Marshall DC, Check JH, Schnell V, Jacobs M, Yemini M, Oskowitz S, Batzofin J, Housermann V, Marrs RP for the mixed protocol study group. A randomized, comparative, 3-arm, parallel group, open-label, multi-center study of the efficacy and safety of Bravelle™ (purified human FSH) and Repronex® when mixed in the same syringe and administered subcutaneously in continuous or sequential dose ratios to patients (18-33 years) undergoing in-vitro fertilization: interim data. Fertil Steril 77: S14, 2002.
DCM.dec07
D.C. Marshall Page 7 of 8
Marshall DC, Webster BW, Najmabadi S, Dickey RP, Crain JL, Somkuti SG, Magarelli P, Elkind Hirsch K, Steinkampf MJ. Highly purified (HP) Repronex SC and HP-Repronex IM are as effective as Repronex SC in a prospective, randomized clinical trial evaluating controlled ovarian hyperstimulation (COH) in patients undergoing in-vitro fertilization (IVF). Fertil Steril 77:S15, 2002.
Marshall DC, Surrey M, VanVoorhis B, Kenigsberg D, Check JH, McShane P, Eisermann J, Scheiber MD, Westphal LM, Keye WR for the mixed protocol study group. A randomized, comparative, 3-arm, parallel group, open-label, multi-center study of the efficacy and safety of Bravelle™ (purified human FSH) and Repronex® when mixed in the same syringe and administered subcutaneously in continuous or sequential dose ratios to patients (34-40 years) undergoing in-vitro fertilization: interim data. Fertil Steril 77: S14, 2002.
Marshall DC, Raike EA, Nardi RV. Mixed protocol same-syringe combination of gonadotropins: compatibility of Ferring’s new highly purified human-derived FSH and Repronex®. Fertil Steril 76:S167, 2001.
Dickey, R.P., Thornton, M, Nichols, J.E., Fein, S.H., Marshall, D.C.: A New Highly Purified Human-Derived FSH is Efficacious and Well-Tolerated in a Prospective, Randomized Clinical Trial of In Vitro
Fertilization. Fertil Steril 76(3), Suppl 1, S73, 2001.
Fein SH, Kaufman R, Gocial B, Marshall DC: Subcutaneous Administration of Ferring’s New Highly Purified, Human-Derived FSH to Female Patients Participating as Egg Donors for IVF is an Effective and Well-Tolerated Treatment. Fertil Steril 76(3), Suppl 1, S168, 2001.
Feigenbaum SL, Fein SH, Miller P, Kaufman R, Marshall DC: A Prospective Randomized Clinical Trial Comparing a New Human-Derived FSH and Recombinant-Derived FSH in Oligoanovulatory Females Undergoing Ovulation Induction. Fertil Steril 76(3), Suppl 1, S116, 2001.
Marshall DC, Raike EA, Nardi RV: Mixed Protocol Same-Syringe Combination of Gonadotropins: Compatability of Ferring’s New Highly Purified Human-Derived FSH and Repronex®. Fertil Steril 76(3), Suppl 1, S167, 2001.
Nardi RV, Dickey RP, Thornton M, Nichols J, Fein SH, Marshall DC: A Randomized, Open-label, Parallel Group, Multi-Center Efficacy Study Comparing Ferring hFSH™ SC, Ferring FSH™ IM and Follistim® SC in Female Patients Undergoing In Vitro Fertilization. Fertil Steril, 75(4),Suppl 1, 13S, 2001.
Nardi R.V., Feigenbaum S., Miller P., Kaufmann R., Fein S.H., Marshall, D.C.: A Randomized, Open-Label, Parallel Group, Multicenter Efficacy Study in Oligoanovulatory Infertile Patients Comparing Comparing Ferring hFSH™ SC, Ferring FSH™ IM and Follistim® SC for Ovulation Induction. Fertil Steril, 75(4),Suppl 1, 13S, 2001.
Lampe, J.W., Hanna, R.G., Piscitelli, T.A., Chou, Y.L., Erhardt, P.W., Lumma, W.C. Jr., Greenberg, S.S., Ingebretsen, W.R., Marshall, D.C., Wiggins, J.: Histamine Analogues as Potential Cardiovascular Selective H2 Agonists. Abs. Am. Chem. Soc.: V198, 69, 1989.
Marshall, D.C. and Buccafusco, J.J.: Mechanism of Morphine Withdrawal in Spinal-Transected Rats. Neurosci. Abs. 10 (2): 930, 1984.
Buccafusco, J.J. and Marshall, D.C.: Spontaneous Morphine Withdrawal From the Spinal Cord After C-1 Section in Dependent Rats. Neurosci. Abs. 10 (2): 1113, 1984.
Turner, R.M., Marshall, D.C. and Buccafusco, J.J.: Supraspinal and Spinal Components of Naloxone Induced Morphine Withdrawal. The Pharmacologist 26 (3): 197, 1984.
DCM.dec07
D.C. Marshall Page 8 of 8
Marshall, D.C. and Buccafusco, J.J.: Role of Cholinergic Neurons in the Spinal Component of Morphine Withdrawal. The Pharmacologist 26 (3): 197, 1984.
Buccafusco, J.J. and Marshall, D.C.: Spinal Cholinergic Neurons Mediate a Hypertensive Response. The Pharmacologist 26 (3): 238, 1984.
Marshall, D.C. and Buccafusco, J.J.: Cardiovascular and Behavioral Changes Associated With Narcotic Withdrawal During the Development of Physical Dependence. Proc. Soc. Exp. Biology Med. 176 (2): 216, 1984.
Marshall, D.C. and Buccafusco, J.J.: Cardiovascular Changes During Naloxone Precipitated Withdrawal: An Index of the Degree of Physical Dependence. Trans. Proc. S.E. Pharmacol.Soc. 4: 23, 1983.
Marshall, D.C., Aronstam, R.S. and Carrier, G.O.: Muscarinic Agonists and Barium-Induced 45Calcium Influx in Guinea Pig Ileum: Influence of Alkylation. Fed. Proc. 42 (4): 1146, 1983.
Marshall, D.C. and Buccafusco, J.J.: Role of Central Adrenergic and Cholinergic Neurons in the Pressor Response Associated with Morphine Withdrawal. Proc. Soc. Exp. Biology Med. 172 (1): 130, 1983.
Marshall, D.C., Aronstam, R.S. and Buccafusco, J.J.: Biochemical and Physiological Activity of Acetylcholine Analogues. Trans. Proc. S.E. Pharmacol. Soc. 3: 19, 1982.
Marshall, D.C., Aronstam, R.S. and Carrier, G.O.: Calcium Fluxes Induced by Barium and Muscarinic Agonists in Guinea Pig Ileum: Influence of Alkylation. Trans.Proc. S.E. Pharmacol. Soc. 3:19, 1982.
Aronstam, R.S., Marshall, D.C. and Buccafusco, J.J.: Biochemical and Physiological Activity of Acetylmonoethylcholine. Fed. Proc. 41: 1308, 1982.
Author of more than 200 clinical study reports, regulatory reports/IRDs/INDs/NDAs/Supplements, product monographs and position papers in the public domain; a listing is available.